Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.
Therapeutic inhibition of the miR-34 family (miR-34a,-b,-c), or miR-34a alone, have emerged as promising strategies for the treatment of cardiac pathology. However, before advancing these approaches further for potential entry into the clinic, a more comprehensive assessment of the therapeutic poten...
Guardat en:
| Autors principals: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science (PLoS)
2014-01-01
|
| Col·lecció: | PLoS ONE |
| Accés en línia: | https://doi.org/10.1371/journal.pone.0090337 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
